



OPAL BIOSCIENCES LIMITED

ABN 97 605 631 963

Level 4,

100 Albert Road,

South Melbourne, Victoria, 3205

Australia

Phone: +613 9692 7240

Web: www.opalbiosciences.com

Opal Biosciences Leads Proposal for Biotech Precinct

Key highlights:

- Initiative to create life sciences precinct to facilitate academic and industry collaboration
- Focus on building Australian capability in development and manufacture of medicines and vaccines
- Ecosystem will promote commercialization and manufacture for market and economic returns
- Expressions of interest sought from Australian and overseas parties to join precinct proposal

Melbourne, 22 Jun 2021: Opal Biosciences Ltd (“Opal”) is pleased to call for expressions of interest from companies and organizations wishing to support and/or participate in the formation of a *Life Sciences and Biotechnology Development and Manufacturing Precinct* in 2023 to be based in Boronia, Victoria, Australia. Expressions of interest are sought by 31 July 2021. The precinct would open in 2023 with off-site preparatory work and planning to be undertaken during 2022.

In 2020 GSK announced the closure of its large pharmaceutical manufacturing plant in Boronia by the end of 2022. Opal proposes to lease the site and seeks other interested parties for use of the extensive existing infrastructure including areas of office spaces, laboratories and manufacturing facilities or for development of bespoke requirements on vacant areas of the site.

Opal encourages academic and medical research institutions as well as local and overseas companies to consider this opportunity. The precinct will facilitate collaboration with industry partners and assistance for pharmaceutical development and manufacture on the site. Experienced industry input would expedite translation of academic and medical research to commercial development and manufacture. Service providers are also encouraged to be part of the precinct.

Opal’s Managing Director, Julie Phillips said, “The Opal vision is ambitious - it is an exciting and much needed initiative for Australia and would be the first of its type here. We have already attracted enormous support from experts and companies in vaccine and pharmaceutical manufacture as well as intellectual property, quality systems, regulatory, preclinical and commercialization service providers. This ecosystem will guide companies and other groups in the development and manufacturing of their pharmaceutical and vaccine assets, and importantly, do it here in Australia”.

Opal’s strategic focus is now directed towards growing Australia’s vaccine and pharmaceutical manufacturing capability which has become evident as a sovereign need during the recent pandemic. As its first step Opal has committed to the acquisition of Formulytica Pty Ltd to grow contract manufacturing capability to support clinical trials. This was announced last month and is the subject of Opal’s current capital raising. Formulytica’s

formulation and development expertise is an important component of Opal's proposal for a life sciences precinct. Opal's recently announced alliance with Biointelect highlights its focus on facilitating Australian R&D medicine development, commercialization and manufacturing. Expressions of interest can be sent to jphillips@opalbiosciences.com.

- ENDS -

About Opal Biosciences Ltd

Opal Biosciences is an Australian biotechnology company and an innovative player in infectious disease treatment. Opal is currently seeking to diversify its focus by considering commercial opportunities within the Australian biotechnology and pharmaceutical industry and is undertaking a capital raising to acquire Formulytica Pty Ltd.

For more information, please visit www.opalbiosciences.com.

About Formulytica Pty Ltd

Formulytica is an Australian innovative technology developer and service provider specialising in topical and injectable formulation development. Formulytica's services include new product development and it specializes in the analytical science of semi-solid formulations for topical application utilised in dermatology, pharmaceutical, cosmetic, veterinary and personal care products, such as skincare and haircare. Formulytica's injectable parenteral expertise covers solution and lipid-based formulations, in biologics, as well as small organic molecules.

For more information, please visit www.formulytica.com.

About Biointelect

Biointelect is a strategic planning and market research firm for the biopharmaceutical and medical device sector including academic, commercial, government and not-for-profit organisations. Biointelect helps clients to develop and drive their R&D, commercial and market entry strategy. We advise clients on the spectrum of therapeutic development from start up through to post launch, with an Australian and a Global perspective.

For more information, please visit www.biointelect.com.

Further information

Julie Phillips, Managing Director, Opal Biosciences Ltd

Phone +61 3 9692 7222

Email jphillips@opalbiosciences.com

Twitter @opalbiosciences